Get the Daily Brief
Latest Biotech News
Axonal translation switch: eIF5A hypusination eases FUS‑ALS
Researchers report that hypusination of the translation factor eIF5A regulates local protein synthesis in axons and mitigates pathology in models of FUS‑linked amyotrophic lateral sclerosis (ALS),...
Ipsen doubles down on ADCs: $1.06B LRRC15 deal with Simcere
Ipsen signed an ex‑China agreement to access SIM0613, an LRRC15‑targeting antibody‑drug conjugate (ADC) from Shanghai’s Simcere, in a deal that could be worth as much as $1.06 billion, the company...
Aktis heads for market: IPO to bankroll Lilly‑partnered radiopharma trials
Aktis Oncology filed for an initial public offering to finance clinical development of its miniprotein radioconjugates, the company disclosed in regulatory filings and media reports. The...
AstraZeneca bets and stumbles: $100M pan‑KRAS buy amid phase‑3 lung failure
AstraZeneca paid $100 million upfront to secure ex‑China rights to Jacobio Pharma’s clinical‑stage pan‑KRAS inhibitor JAB‑23E73, expanding its oncology footprint, company releases show....
Boehringer inks $448M pact with Rectify to develop oral CKD drugs
Boehringer Ingelheim agreed to collaborate with Boston startup Rectify to develop oral therapies for chronic kidney disease in a deal worth up to $448 million in biobucks. The partnership names...
Windward buys Qyuns bispecific: up to $700M for dual TSLP–IL‑13 program
Windward Bio agreed to acquire ex‑China rights to Qyuns Therapeutics’ WIN027 (QX027N), a long‑acting bispecific targeting TSLP and IL‑13, in a deal with headline value up to $700 million....
FDA clears Cytokinetics’ Myqorzo – first approval and a direct rival to Camzyos
The Food and Drug Administration approved Cytokinetics’ Myqorzo, marking the company’s first approved drug and setting up a direct commercial competitor to Bristol Myers Squibb’s Camzyos....
Antisense rescue: therapy reverses developmental defects in SMA organoids
A Nature Communications study shows that targeted antisense oligonucleotide (ASO) therapy reverses developmental defects in spinal muscular atrophy (SMA) organoid models. Investigators reported...
Autophagy steers CD8+ fate: mitochondrial inheritance controls T‑cell memory
Teams at the Max Delbrück Center and the University of Oxford reported in Nature Cell Biology that autophagy regulates asymmetric mitochondrial inheritance during early CD8+ T‑cell divisions,...
Artificial metabolism and ReForm: converting CO2 into biological building blocks
Two synthetic‑biology teams unveiled complementary advances to capture one‑carbon feedstocks and convert them into central metabolites. Northwestern and Stanford researchers reported an artificial...
AstraZeneca’s synthetic‑lethal program falters; bets $100M on pan‑KRAS
AstraZeneca reported a phase 3 failure for ceralasertib in lung cancer, missing the study’s primary endpoint and undermining a synthetic‑lethal strategy meant to overcome immuno‑oncology...
FDA clears Cytokinetics’ heart drug — challenger to Bristol Myers
The FDA approved Cytokinetics’ Myqorzo, marking the company’s first marketed therapy and placing it in direct commercial competition with Bristol Myers Squibb’s Camzyos in hypertrophic...
Samsung Biologics buys GSK U.S. plant for $280 million
Samsung Biologics agreed to acquire a U.S. drug production facility from GlaxoSmithKline for $280 million, a deal that expands the CDMO’s manufacturing footprint in North America. The transaction...
U.S. funding freeze and vaccine schedule overhaul — researchers raise alarms
The U.S. government’s 2025 actions froze major research functions at the NIH and canceled more than $1.5 billion in grants, creating uncertainty for clinical trials, early‑career scientists, and...
Biohacking trial: Unlimited Bio to inject healthy volunteers with gene therapies
Unlimited Bio announced plans to inject a small cohort of healthy volunteers with two experimental gene therapies aimed at boosting muscle blood supply and growth, and ultimately pursuing...
Antisense oligonucleotide rescues SMA organoids — developmental defects reversed
Researchers reported in Nature Communications that targeted antisense oligonucleotide (ASO) therapy reversed developmental defects in spinal muscular atrophy (SMA) organoid models. The lead...
Engineered metabolism converts CO₂ into biological building blocks
Synthetic biologists at Northwestern and Stanford engineered an artificial metabolic pathway that converts waste CO₂ into useful biological precursors. The lead finding: the team designed a...
Researchers engineer microbes to break down microplastics
A team reported engineering microbial strains capable of digesting microplastics, outlining enzymatic pathways and biodegradation routes for plastic polymers. The lead sentence: engineered...
Fruquintinib plus sintilimab shows activity in advanced endometrial cancer
A multicenter Phase Ib/II trial reported that the anti‑angiogenic tyrosine kinase inhibitor fruquintinib combined with the PD‑1 inhibitor sintilimab produced clinical responses in patients with...
Graph‑attention network improves drug‑synergy prediction
Researchers unveiled KGLGANSynergy, a knowledge‑graph and local/global attention network that increases accuracy in predicting drug synergy across compound pairs. The lead sentence: the model...